Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-887-1471
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees11
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable
Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions
What is Eidos Therapeutics' stock symbol?
Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."
How were Eidos Therapeutics' earnings last quarter?
Eidos Therapeutics Inc (NASDAQ:EIDX) posted its earnings results on Monday, April, 15th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. View Eidos Therapeutics' Earnings History.
When is Eidos Therapeutics' next earnings date?
What price target have analysts set for EIDX?
7 brokerages have issued 12-month price targets for Eidos Therapeutics' shares. Their forecasts range from $13.00 to $40.00. On average, they anticipate Eidos Therapeutics' stock price to reach $30.2857 in the next year. This suggests a possible upside of 13.5% from the stock's current price. View Analyst Price Targets for Eidos Therapeutics.
What is the consensus analysts' recommendation for Eidos Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eidos Therapeutics.
Has Eidos Therapeutics been receiving favorable news coverage?
News stories about EIDX stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eidos Therapeutics earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Eidos Therapeutics' key competitors?
Some companies that are related to Eidos Therapeutics include Alkermes (ALKS), ACADIA Pharmaceuticals (ACAD), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Mirati Therapeutics (MRTX), Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX) and The Medicines (MDCO).
What other stocks do shareholders of Eidos Therapeutics own?
Who are Eidos Therapeutics' key executives?
Eidos Therapeutics' management team includes the folowing people:
- Dr. Neil Kumar, CEO & Director (Age 40)
- Dr. Jonathan C. Fox FACC, M.D., Ph.D., Pres & Chief Medical Officer (Age 62)
- Dr. Uma Sinha, Chief Scientific Officer (Age 62)
- Dr. Hoyoung Huh, Consultant (Age 50)
- Ms. Christine E. Siu, Chief Financial Officer (Age 42)
When did Eidos Therapeutics IPO?
(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Barclays was co-manager.
Who are Eidos Therapeutics' major shareholders?
Eidos Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.38%), Candriam Luxembourg S.C.A. (1.15%), American International Group Inc. (0.67%), Opaleye Management Inc. (0.54%), Schonfeld Strategic Advisors LLC (0.50%) and Victory Capital Management Inc. (0.50%). Company insiders that own Eidos Therapeutics stock include Bridgebio Pharma Llc, Christine Siu, Jonathan C Fox, Neil Kumar and Rajeev M Shah. View Institutional Ownership Trends for Eidos Therapeutics.
Which major investors are selling Eidos Therapeutics stock?
EIDX stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Victory Capital Management Inc., Morgan Stanley and Oppenheimer Asset Management Inc.. Company insiders that have sold Eidos Therapeutics company stock in the last year include Bridgebio Pharma Llc, Christine Siu and Jonathan C Fox. View Insider Buying and Selling for Eidos Therapeutics.
Which major investors are buying Eidos Therapeutics stock?
EIDX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Candriam Luxembourg S.C.A., Schonfeld Strategic Advisors LLC, Northern Trust Corp, Opaleye Management Inc., Geode Capital Management LLC, Charles Schwab Investment Management Inc. and Rhumbline Advisers. Company insiders that have bought Eidos Therapeutics stock in the last two years include Bridgebio Pharma Llc, Neil Kumar and Rajeev M Shah. View Insider Buying and Selling for Eidos Therapeutics.
How do I buy shares of Eidos Therapeutics?
Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eidos Therapeutics' stock price today?
One share of EIDX stock can currently be purchased for approximately $26.69.
How big of a company is Eidos Therapeutics?
Eidos Therapeutics has a market capitalization of $982.99 million. The company earns $-33,290,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Eidos Therapeutics employs 11 workers across the globe.
What is Eidos Therapeutics' official website?
How can I contact Eidos Therapeutics?
Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]
MarketBeat Community Rating for Eidos Therapeutics (NASDAQ EIDX)
MarketBeat's community ratings are surveys of what our community members think about Eidos Therapeutics and other stocks. Vote "Outperform" if you believe EIDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
